TY  - JOUR
A1  - Lee-Theilen, Mieun
A1  - Hadhoud, Julia R.
A1  - Volante, Giulietta
A1  - Fadini, Delaine D.
A1  - Eichhorn, Julia
A1  - Rolle, Udo
A1  - Fiege, Henning C.
T1  - Co-expression of CD34, CD90, OV-6 and cell-surface vimentin defines cancer stem cells of hepatoblastoma, which are affected by Hsp90 inhibitor 17-AAG
T2  - Cells
N2  - Cancer stem cells (CSCs) are nowadays one of the major focuses in tumor research since this subpopulation was revealed to be a great obstacle for successful treatment. The identification of CSCs in pediatric solid tumors harbors major challenges because of the immature character of these tumors. Here, we present CD34, CD90, OV-6 and cell-surface vimentin (csVimentin) as reliable markers to identify CSCs in hepatoblastoma cell lines. We were able to identify CSC characteristics for the subset of CD34+CD90+OV-6+csVimentin+-co-expressing cells, such as pluripotency, self-renewal, increased expression of EMT markers and migration. Treatment with Cisplatin as the standard chemotherapeutic drug in hepatoblastoma therapy further revealed the chemo-resistance of this subset, which is a main characteristic of CSCs. When we treated the cells with the Hsp90 inhibitor 17-AAG, we observed a significant reduction in the CSC subset. With our study, we identified CSCs of hepatoblastoma using CD34, CD90, OV-6 and csVimentin. This set of markers could be helpful to estimate the success of novel therapeutic approaches, as resistant CSCs are responsible for tumor relapses.
KW  - cancer stem cells
KW  - hepatoblastoma
KW  - CSC marker
KW  - Hsp90 inhibitor
KW  - 17-AAG
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63450
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-634501
SN  - 2073-4409
VL  - 10
IS  - 10, art. 2598
SP  - 1
EP  - 16
PB  - MDPI
CY  - Basel
ER  -